1. Home
  2. MIRM vs KEN Comparison

MIRM vs KEN Comparison

Compare MIRM & KEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • KEN
  • Stock Information
  • Founded
  • MIRM 2018
  • KEN 2014
  • Country
  • MIRM United States
  • KEN Singapore
  • Employees
  • MIRM N/A
  • KEN N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • KEN Electric Utilities: Central
  • Sector
  • MIRM Health Care
  • KEN Utilities
  • Exchange
  • MIRM Nasdaq
  • KEN Nasdaq
  • Market Cap
  • MIRM 2.5B
  • KEN 2.2B
  • IPO Year
  • MIRM 2019
  • KEN N/A
  • Fundamental
  • Price
  • MIRM $52.17
  • KEN $48.25
  • Analyst Decision
  • MIRM Strong Buy
  • KEN
  • Analyst Count
  • MIRM 9
  • KEN 0
  • Target Price
  • MIRM $66.22
  • KEN N/A
  • AVG Volume (30 Days)
  • MIRM 413.0K
  • KEN 21.9K
  • Earning Date
  • MIRM 08-06-2025
  • KEN 09-08-2025
  • Dividend Yield
  • MIRM N/A
  • KEN 9.95%
  • EPS Growth
  • MIRM N/A
  • KEN N/A
  • EPS
  • MIRM N/A
  • KEN 11.35
  • Revenue
  • MIRM $379,251,000.00
  • KEN $760,304,000.00
  • Revenue This Year
  • MIRM $35.83
  • KEN N/A
  • Revenue Next Year
  • MIRM $16.83
  • KEN N/A
  • P/E Ratio
  • MIRM N/A
  • KEN $4.16
  • Revenue Growth
  • MIRM 69.31
  • KEN 5.78
  • 52 Week Low
  • MIRM $36.20
  • KEN $23.31
  • 52 Week High
  • MIRM $54.78
  • KEN $49.99
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 56.47
  • KEN 73.00
  • Support Level
  • MIRM $50.96
  • KEN $46.51
  • Resistance Level
  • MIRM $53.59
  • KEN $49.99
  • Average True Range (ATR)
  • MIRM 1.63
  • KEN 0.74
  • MACD
  • MIRM -0.17
  • KEN 0.08
  • Stochastic Oscillator
  • MIRM 53.06
  • KEN 71.61

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About KEN Kenon Holdings Ltd.

Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented businesses. The company's operating segments include OPC Power Plants, CPV Group, and ZIM. It generates maximum revenue from the OPC Power Plants segment, which generates and supplies electricity and energy in Israel. CPV Group is a limited partnership owned by OPC, which generates and supplies electricity and energy in the United States. Geographically, the company generates a majority of its revenue from Israel and the rest from the United States.

Share on Social Networks: